Jack Hoppin
Chief Executive Officer Ratio Therapeutics
Dr. Jack Hoppin is the Chairman and CEO of Ratio Therapeutics, a Boston-based company specializing in the development of targeted radiopharmaceuticals for cancer treatment. With over two decades of experience in biotechnology and precision medicine, Dr. Hoppin co-founded Invicro, and has held leadership roles at Konica Minolta Precision Medicine, Bioscan, Inc. and Emit Imaging. He earned his PhD in Applied Mathematics from the University of Arizona and continued his training as an Alexander von Humboldt Post-Doctoral Fellow at the Research Center Juelich. In his upcoming session, Dr. Hoppin will share insights from his extensive experience in advancing radiopharmaceuticals.
Seminars
• Sharing how the radiopharmaceuticals field is rapidly advancing, with growing clinical data shaping our understanding of pharmacokinetics, efficacy, and safety
• Examining where we stand and where we are heading across the landscape of therapeutic and diagnostic platforms
• Exploring radiation dosimetry, regulatory considerations, and manufacturing—highlighting key learnings and emerging challenges
